HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a $16 price target.
March 25, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Esperion Therapeutics maintains a Buy rating and a $16 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $16 price target by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for Esperion Therapeutics. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100